DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Agency for Toxic Substances and Disease Registry; Senior Executive Service; Performance Review Board Members

AGENCY: Centers for Disease Control and Prevention (CDC), and Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: Title 5, U.S. Code, Section 4314 (c) (4) of the Civil Service Reform Act of 1978, Public Law 95–454, requires that appointment of Performance Review Board members be published in the Federal Register.

FOR FURTHER INFORMATION CONTACT: Connie Clayton, Human Resources Management Office, Office of Program Support, Centers for Disease Control and Prevention, 4770 Buford Highway, Mailstop K–07, Atlanta, Georgia 30341–3724, (770) 488–1785.

SUPPLEMENTARY INFORMATION: The following persons will serve on the Performance Review Board which oversees the evaluation of performance appraisals of Senior Executive Service members of the Department of Health and Human Services in the Centers for Disease Control and Prevention, and the Agency for Toxic Substances and Disease Registry:

Claire V. Broome, M.D., Chairperson

William D. Adams

Helene D. Gayle, M.D., M.P.H.

James M. Hughes, M.D.

Arthur C. Jackson

Richard J. Jackson, M.D., M.P.H.

Wanda K. Jones, Dr.P.H.

James S. Marks, M.D., M.P.H.

Linda Rosenstock, M.D., M.P.H.

Dated: November 5, 1996.

Claire Broome,

Deputy Director, Centers for Disease Control and Prevention (CDC) and Deputy Administrator, Agency for Toxic Substances and Disease Registry (ATSDR).

[FR Doc. 96–28896 Filed 11–8–96; 8:45 am]

BILLING CODE 4163–18–P

Food and Drug Administration

[Docket No. 96N–0340]

Lilly Research Laboratories, et al.; Withdrawal of Approval of 12 New Drug Applications, 8 Abbreviated Antibiotic Applications, and 23 Abbreviated New Drug Applications; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of October 2, 1996 (61 FR 51457). The document announced the withdrawal of approval of 12 new drug applications (NDA's), 8 abbreviated antibiotic applications (AADA's), and 23 abbreviated new drug applications (ANDA's). That document inadvertently withdrew approval of all of NDA 18–830 for Tambocor (flecainide acetate) 50, 100, 150, and 200 milligrams (mg) tablets held by 3M Pharmaceuticals, 3M Center, Bldg. 270–3A–01, St. Paul, MN 55144–1000. This notice confirms that approval of NDA 18–830 is still in effect, and approval is withdrawn only of portions pertaining to the 200 mg tablet.

EFFECTIVE DATE: October 2, 1996.

FOR FURTHER INFORMATION CONTACT: Olivia A. Vieira, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1046.

In FR Doc. 96–25198, appearing on page 51457 in the Federal Register of Wednesday, October 2, 1996, the following correction is made: On page 51457, in the second column, in the table, the entry for NDA 18–830 is corrected to read ''Tambocor (flecainide acetate), 200 mg Tablets (only those portions of the NDA that deal with 200 mg tablets).''

Dated: October 29, 1996.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 96–28931 Filed 11–8–96; 8:45 am]

BILLING CODE 4160–01–F

Health Resources and Services Administration

Agency Information Collection Activities: Proposed Collection; Comment Request

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Health Resources and Services Administration (HRSA) will publish periodic summaries of proposed projects being developed for submission to OMB under the Paperwork Reduction Act of 1995. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, call the HRSA Reports Clearance Officer on (301) 443–1129.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Project

A Study of Physicians' Educational Preparation for Practice in Managed Care—(0915–0202)—Reinstatement— OMB approval was obtained in 1995 to conduct two mail surveys, one of primary care physicians and one of medical directors in managed care organizations (MCOs). The purpose of both is to assess their views of the adequacy of physician preparation for practice in a managed care setting. Data collection began in June 1996. Early responses indicated that a high proportion of the sampled physicians were not eligible for the survey, which was targeted to primary care physicians in group and staff model MCOs. Methods for increasing the proportion of eligibles to an acceptable rate are being explored, including the possibility of conducting brief screening phone calls to determine eligibility prior to mailing the questionnaires. Once a methodology has been selected and OMB approval is reinstated, data collection will resume. Few, if any, substantive changes to the questionnaire are expected. Note that the survey of medical directors had acceptable eligibility rates, and data collection is proceeding.

The survey of physicians will be limited to allopathic primary care physicians who graduated between 1986 and 1990. The information will be used by the Bureau of Health Professions to formulate recommendations for curriculum changes in medical